Article
A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
Investigational new drugs - 1 Oct 2018
van der Biessen Diane A J, Gietema Jourik A, de Jonge Maja J A, Desar Ingrid M E, den Hollander Martha W, Dudley Matthew, Dunbar Martin, Hetman Robert, Serpenti Camille, Xiong Hao, Mittapalli Rajendar K, Timms Kirsten M, Ansell Peter, Ratajczak Christine K, Shepherd Stacie Peacock, van Herpen Carla M L
Abstract excerpt
Purpose This phase 1 study examined safety, pharmacokinetics (PK), and efficacy of the poly(ADP-ribose) polymerase (PARP) inhibitor ABT-767 in patients with advanced solid tumors and BRCA1/2 mutations or with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. Methods Patients received ABT-767 monotherapy orally until disease progression or unacceptable toxicity. Dose was escalated from 20 mg...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.